Dr Sheena McCormack (UCL MRC Clinical Trials Unit) who coordinated the Proud study in 2014, says the drop in new diagnoses correlates with their findings which showed an 86% fall in new infections among those taking the drug, pre-exposure prophylaxis.
Read: The Guardian
Close
